Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.8/5
3SBio Inc (1530 HK)
Watchlist
Contact IR
118
Analysis
Health Care
•
China
3SBio, Inc. is a biotechnology company located in China. The Company focuses on mammalian cell-based biopharmaceuticals in the biotechnology industry. 3SBio also develops, manufactures and markets biopharmaceutical products globally.
more
Watchlist
Contact IR
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
3SBio Inc
•
01 Jul 2025 00:30
3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?
3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...
Tina Banerjee
Follow
167 Views
Share
bearish
•
China Traditional Chinese Medicine
•
18 Oct 2024 15:12
China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price
This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...
Arun George
Follow
1.3k Views
Share
bullish
•
Quantitative Analysis
•
29 Jun 2025 02:15
HK Short Interest Weekly: Baba, Chow Tai Fook, Za Online, Cspc Pharma, BOC, Petrochina
We analyzed the latest HK SFC report for aggregate short position as of Jun 20th and highlight short interest changes in Baba, Chow Tai Fook, Za...
Ke Yan, CFA, FRM
Follow
216 Views
Share
bearish
•
Innovent Biologics Inc
•
29 Jun 2025 01:19
China Healthcare Weekly (Jun.29) - Biotech Valuation Bubble Is About to Burst, Innovent's Placement
The valuation bubble of innovative drug companies may burst soon, with some founders/shareholders already cashing out. Innovent's Placing Price of...
Xinyao (Criss) Wang
Follow
284 Views
Share
bearish
•
Thematic (Sector/Industry)
•
23 Jun 2025 04:48
•
Syndicated
Chinese Biotech Innovators Push Overseas as Sector Faces Reckoning
After years of falling valuations and stalled IPO activity, China’s innovative drug industry is showing early signs of a comeback. A spate of...
Caixin Global
Follow
202 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.7
x